Results 81 to 90 of about 5,562,127 (298)

Pilot study: Evaluation of potential drug–drug interactions in hospitalized pediatric patients

open access: yesPediatrics and Neonatology, 2020
Purpose: Evaluate the type and severity of potential drug-drug interactions and identify risk factors involved, in pediatric patients admitted in a hospital setting.
Fabiola Medina-Barajas   +6 more
doaj   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

open access: yesFEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg   +14 more
wiley   +1 more source

Training toolkit on drug policy advocacy.

open access: yes, 2013
This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making ...

core  

Drug interactions and hepatotoxicity of clopidogrel [PDF]

open access: yes, 2010
Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

‘Civil society involvement in drug policy’ webinar.

open access: yes, 2018
On 30th November 2018, Ana Liffey Drug Project hosted a webinar about Civil Society Involvement in Drug Policy. The event included interviews with: Anna Quigley (CityWide) Tony Duffin (Ana Liffey Drug Project) Aoife Frances (National Family Support ...

core  

Introduction to drug utilization research [PDF]

open access: yes, 2003
Prepared by the WHO Collaborating Centre for Drug Statistics Methodology, the WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, and the International Working Group for Drug Statistics Methodology48 p.Korean ...
WHO International Working Group for Drug Statistics Methodology   +2 more
core  

Local and global modes of drug action in biochemical networks [PDF]

open access: yes, 2008
It becomes increasingly accepted that a shift is needed from the traditional target-based approach of drug development to an integrated perspective of drug action in biochemical systems. We here present an integrative analysis of the interactions between
Schwartz, Jean Marc; id_orcid   +4 more
core   +1 more source

Conformational analysis of fenoterol stereoisomers

open access: yesCurrent Issues in Pharmacy and Medical Sciences
Fenoterol is a relatively long-acting selective agonist of β2 adrenergic receptor (β2-AR) used in the treatment of asthma. Its molecule contains two stereogenic centers, thus, the compound exists as four stereoisomers.
Anita Płazińska   +2 more
doaj  

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy